Composite Scaffold with Ion Exchange Lamellar Solids for Soft Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dermal substitutes for soft tissue reconstruction face challenges such as long integration times and infections, which can lead to procedure failure and increased healthcare costs, and existing scaffolds lack the ability to simultaneously load and slowly release both anionic and cationic active ingredients effectively.
Innovation Solution
A composite scaffold comprising a bio-resorbable matrix and lamellar solids with ion exchange properties, which can selectively adsorb active ingredients before grafting and release them gradually, allowing for the simultaneous incorporation of both anionic and cationic active ingredients without the need for binders, and can be loaded with a wide range of therapeutic agents in the operating room.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional skin grafts and tissue flaps are used for soft tissue reconstruction, then the surgical procedure can be performed, but severe scarring occurs with aesthetic and functional consequences and hospitalization times are long
Solution Approach 1:
The scaffold is pre-loaded with active ingredients (antibiotics, growth factors, anti-inflammatories) before implantation, allowing therapeutic action to begin immediately upon grafting without requiring postoperative hospitalization for medication administration
Solution Approach 2:
The scaffold provides self-contained therapeutic functionality through integrated active ingredients that are released autonomously over time, eliminating the need for external pharmaceutical intervention and reducing hospitalization requirements
2Reliability
If dermal substitutes are used to avoid donor area scarring, then aesthetic deficits are improved, but integration time is extended and infections occur leading to procedure failure
Solution Approach 1:
Active ingredients are loaded into the scaffold before implantation, initiating the integration process immediately upon grafting. The scaffold is pre-prepared to promote vascularization and cellular colonization from the outset, reducing the overall integration time
Solution Approach 2:
The scaffold provides continuous release of active ingredients over an extended period, maintaining therapeutic action throughout the integration process. This sustained release promotes continuous vascularization and cellular infiltration, ensuring reliable integration without prolonged hospitalization
3Object-affected harmful factors
If dermal substitutes are used instead of traditional grafts, then donor area damage is avoided, but infections are frequent and harmful leading to loss of the dermal substitute
Solution Approach 1:
Antibiotics and anti-inflammatories are loaded into the scaffold before implantation, providing immediate protection against infections at the time of grafting. This preliminary therapeutic preparation prevents bacterial proliferation during the critical initial healing phase
Solution Approach 2:
The scaffold provides continuous anti-infective protection through prolonged release of antibiotics and anti-inflammatories throughout the entire integration period. This sustained therapeutic action maintains procedure success by preventing infections that would otherwise lead to scaffold loss
4Adaptability or versatility
If existing scaffolds are used that can release active ingredients, then some therapeutic benefit is achieved, but they cannot simultaneously incorporate both anionic and cationic active ingredients effectively
Solution Approach 1:
The scaffold incorporates both anionic and cationic lamellar solids with different ion exchange capacities, allowing selective and simultaneous loading of different active ingredients. Each lamellar solid type can be optimized for specific active ingredient classes, enabling tailored therapeutic compositions
Solution Approach 2:
The scaffold system provides universal compatibility with multiple types of active ingredients through the dual lamellar solid structure. The combination of anionic and cationic exchange-capable lamellar solids enables the scaffold to load diverse therapeutic agents including antibiotics, growth factors, and anti-inflammatories simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces infection incidence, improves integration and regeneration quality, and enables personalized therapeutic approaches by providing a scaffold that can be tailored for specific needs, reducing integration times and enhancing the effectiveness of soft tissue regeneration.
Implementation Method 1
lamellar solids with ion exchange properties, which can selectively adsorb active ingredients before grafting
Implementation Method 2
Lamellar solids have the ability to absorb active ingredients in a phase prior the grafting of the scaffold
Implementation Method 3
release them after the scaffold has been grafted in an area of the patient subject to regeneration
Implementation Method 4
bio-resorbable porous matrix... rapidly vascularized by the host's neo-angiogenesis, with consequent engraftment of the graft and colonization of the dermal substitute by the host's cells. This remodelling process, which lasts about 60 days
Data Source
Figure 1A~1D
Figure 2A~2B
Figure 3A~3B
AI summary
A sheet-shaped composite scaffold suitable for implantation in a dermal lesion or in a soft tissue of a patient; the composite scaffold comprises: a bio-resorbable porous matrix and at least one lamellar solid with ion exchange capacity suitable for being loaded with active principles in a pre-operative phase.